Unicycive Therapeutics increases ATM offering capacity from $50M to $100M

Unicycive Therapeutics, Inc.

Amendment No. 1 to Sales Agreement raises aggregate offering price limit from $50M to $100M.
Sales agent remains Guggenheim Securities, LLC; shares sold at market prices under Rule 415.
Company filed a prospectus supplement with the SEC on November 14, 2025, covering the increase.
Legal opinion on share validity from Sheppard Mullin filed as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.